Search research articles
Contact Us
Filters
Showing results (31-40 of 208) with videos related to
Page
of 21
Sort By:
Targeted Oncology
|
April 17, 2026
Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis
Yu Fujiwara, Toshiaki Takahashi, Kazuya Tsuchiya, et al.
Journal of Translational Medicine
|
April 19, 2018
The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017
Paolo A Ascierto, Corrado Caracò, Jeffrey E Gershenwald, et al.
JCO Oncology Practice
|
September 8, 2023
Risk of Further Progression or Death Among Durable Progression-Free Survivors With Melanoma or Non-Small-Cell Lung Cancer in PD-1 Blockade Trials: Implications for Imaging Surveillance
Lei Deng, Changchuan Jiang, Kristopher Attwood, et al.
Cancer Immunology Research
|
May 20, 2016
Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab
Amanda Shreders, Richard Joseph, Chengwei Peng, et al.
Expert Review of Anticancer Therapy
|
November 13, 2015
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy
Kevin J Harrington, Igor Puzanov, J Randolph Hecht, et al.
Journal for Immunotherapy of Cancer
|
January 21, 2017
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
Kathryn E Beckermann, Pradeep C Jolly, Ju Y Kim, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2017
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
Howard L Kaufman, Robert H I Andtbacka, Frances A Collichio, et al.
Journal for Immunotherapy of Cancer
|
June 14, 2020
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
John Haanen, Marc Ernstoff, Yinghong Wang, et al.
Journal of Translational Medicine
|
April 22, 2023
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022
Paolo A Ascierto, Renier Brentjens, Samir N Khleif, et al.
Journal of Neuro-Oncology
|
May 11, 2017
A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases
Kyle Arneson, Joshua Mondschein, Mark Stavas, et al.
Page
of 21
Search research articles
Search
Showing results (31-40 of 208) with videos related to
Sort By:
Page
of 21
Targeted Oncology
|
April 17, 2026
Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis
Yu Fujiwara, Toshiaki Takahashi, Kazuya Tsuchiya, et al.
Journal of Translational Medicine
|
April 19, 2018
The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017
Paolo A Ascierto, Corrado Caracò, Jeffrey E Gershenwald, et al.
JCO Oncology Practice
|
September 8, 2023
Risk of Further Progression or Death Among Durable Progression-Free Survivors With Melanoma or Non-Small-Cell Lung Cancer in PD-1 Blockade Trials: Implications for Imaging Surveillance
Lei Deng, Changchuan Jiang, Kristopher Attwood, et al.
Cancer Immunology Research
|
May 20, 2016
Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab
Amanda Shreders, Richard Joseph, Chengwei Peng, et al.
Expert Review of Anticancer Therapy
|
November 13, 2015
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy
Kevin J Harrington, Igor Puzanov, J Randolph Hecht, et al.
Journal for Immunotherapy of Cancer
|
January 21, 2017
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
Kathryn E Beckermann, Pradeep C Jolly, Ju Y Kim, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2017
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
Howard L Kaufman, Robert H I Andtbacka, Frances A Collichio, et al.
Journal for Immunotherapy of Cancer
|
June 14, 2020
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
John Haanen, Marc Ernstoff, Yinghong Wang, et al.
Journal of Translational Medicine
|
April 22, 2023
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022
Paolo A Ascierto, Renier Brentjens, Samir N Khleif, et al.
Journal of Neuro-Oncology
|
May 11, 2017
A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases
Kyle Arneson, Joshua Mondschein, Mark Stavas, et al.
Page
of 21